Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryAug142017	Fate Therapeutics Reports Second Quarter 2017 Financial Results First Subject Treated with FATE-NK100 in VOYAGE for Acute Myelogenous Leukemia FDA Clears Investigational New Drug Applications for FATE-NK100 in Recurrent Ovarian Cancer and in Advanced Solid Tumors with Monoclonal Antibody Therapy Company Convenes PROTECT Data Monitoring Committee for ProTmune™ Read All »	View HTML Fate Therapeutics Reports Second Quarter 2017 Financial Results 37.5 KB
Toggle SummaryAug062018	Fate Therapeutics Reports Second Quarter 2018 Financial Results and Highlights Operational Progress Treated 20 th Subject in Phase 2 PROTECT Study of ProTmune Opened Second Site for Enrollment of FATE-NK100 DIMENSION Study Submitted First-of-Kind IND to FDA for Universal Off-the-Shelf NK Cell Product FT500 Licensed Novel CAR Constructs from Memorial Sloan Kettering Cancer Center for Off-the-Shelf Read All »	View HTML
Toggle SummaryAug062019	Fate Therapeutics Reports Second Quarter 2019 Financial Results and Highlights Operational Progress No FT500 DLTs Reported at Second Cell Dose Level in Monotherapy Arm or at First Cell Dose Level in Checkpoint Inhibitor Combination Arm in Solid Tumor Study Successfully Completed FT516 GMP Production and Product Release for Initiation of First-ever Clinical Trial of Engineered iPSC-derived Cell Read All »	View HTML
Toggle SummaryAug052020	Fate Therapeutics Reports Second Quarter 2020 Financial Results and Highlights Operational Progress Partial Response Reported with FT596 Monotherapy at First Dose Level in Refractory DLBCL Patient Enrollment Initiated with FT596 in Combination with Rituximab for B-cell Lymphoma IND Cleared for FT538, the First CRISPR-edited, iPSC-derived Cell Therapy , for AML and Multiple Myeloma IND Cleared Read All »	View HTML
Toggle SummaryAug042021	Fate Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Operational Progress First Patient Treated for Relapsed / Refractory ALL in Landmark Phase 1 Clinical Trial of FT819, the First-ever iPSC-derived CAR T-cell Therapy; Off-the-Shelf Product Candidate Derived from Clonal Master iPSC Line with Novel CD19-specific 1XX CAR Integrated into TRAC Locus FT516 Interim Phase 1 Read All »	View HTML
Toggle SummaryAug032022	Fate Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Operational Progress FT596+R Enrollment Ongoing in Multi-dose, Multi-cycle Cohorts for R/R BCL; Initiated Study Start-up for Investigation of FT596+R-CHOP in Newly-diagnosed Patients with Aggressive BCL FT516 RMAT Meeting Scheduled with FDA for 3Q22 to Discuss Registrational Pathways for R/R BCL First Patient Treated Read All »	View HTML
Toggle SummaryAug082023	Fate Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates Phase 1 Study Start-up Ongoing for FT522 ADR-armed, CD19-targeted CAR NK Cell Program for B-cell Lymphoma ; Dose Escalation Designed to Assess 3-dose Treatment Schedule with and without Conditioning Chemotherapy 2H23 IND Submission Planned under ONO Collaboration for FT825/ONO-8250; HER2-targeted Read All »	View HTML
Toggle SummaryNov132013	Fate Therapeutics Reports Third Quarter 2013 Financial Results Cleared Key Milestones for Resumption of ProHema Phase 2 Clinical Trial Selected Wnt7a Protein Analogs for Advancement into IND-Enabling Activities Extended Breadth of Patent Protection for HSC Modulation Platform SAN DIEGO, Nov. 13, 2013 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. Read All »	View HTML Fate Therapeutics Reports Third Quarter 2013 Financial Results 28.6 KB
Toggle SummaryNov112014	Fate Therapeutics Reports Third Quarter 2014 Financial Results Phase 1b PROMPT Study in Pediatric Hematologic Malignancies Open for Enrollment Second Data Review in Phase 2 PUMA Study Expected in 4Q14 Presenting Effects of Ex Vivo Programming on Mobilized Peripheral Blood at ASH SAN DIEGO, Nov. 11, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. Read All »	View HTML Fate Therapeutics Reports Third Quarter 2014 Financial Results 30.1 KB
Toggle SummaryNov032015	Fate Therapeutics Reports Third Quarter 2015 Financial Results Pluripotent Cell Platform for Generating Off-the-Shelf Cancer Immunotherapies to be Presented at ASH 2015 Annual Meeting First-in-Human Clinical Trial of PROTMUNE™ to Prevent Acute GvHD and Severe Infections Planned for 2016 Reached 70% of Target Enrollment for PROHEMA® PUMA Study SAN Read All »	View HTML Fate Therapeutics Reports Third Quarter 2015 Financial Results 27.9 KB

DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.